Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age

Adults aged 50–64 years have a high incidence of symptomatic influenza associated with substantial disease and economic burden each year. We conducted a randomized, controlled trial to compare the immunogenicity and safety of an adjuvanted quadrivalent inactivated influenza vaccine (aIIV4; n = 1027)...

Descripción completa

Detalles Bibliográficos
Autores principales: Poder, Airi, Oberije, Janine, Meyer, Jay, Heymer, Peter, Molrine, Deborah, Versage, Eve, Isakov, Leah, Zhang, Qiuhong, Hohenboken, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611124/
https://www.ncbi.nlm.nih.gov/pubmed/37896932
http://dx.doi.org/10.3390/vaccines11101528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611124/
https://www.ncbi.nlm.nih.gov/pubmed/37896932
http://dx.doi.org/10.3390/vaccines11101528

Ejemplares similares